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Monosomal karyotype in MDS: explaining the poor prognosis?
J Schanz1, H Tu¨chler2, F Sole´3, M Mallo3, E Lun˜o4, J Cervera5, J Grau6, B Hildebrandt7, ML Slovak8, K Ohyashiki9, C Steidl10, C Fonatsch11,
M Pfeilsto¨cker12, T No¨sslinger12, P Valent13, A Giagounidis14, C Aul15, M Lu¨bbert16, R Stauder17, O Krieger18, MM Le Beau19,
JM Bennett20, P Greenberg21, U Germing22 and D Haase1
Monosomal karyotype (MK) is associated with an adverse prognosis in patients in acute myeloid leukemia (AML). This study
analyzes the prognostic impact of MK in a cohort of primary, untreated patients with myelodysplastic syndromes (MDS). A total of
431 patients were extracted from an international database. To analyze whether MK is an independent prognostic marker in MDS,
cytogenetic and clinical data were explored in uni- and multivariate models regarding overall survival (OS) as well as AML-free
survival. In all, 204/431 (47.3%) patients with MK were identiﬁed. Regarding OS, MK was prognostically signiﬁcant in patients with
p4 abnormalities only. In highly complex karyotypes (X5 abnormalities), MK did not separate prognostic subgroups (median OS
4.9 months in MKþ vs 5.6 months in patients without MK, P¼ 0.832). Based on the number of abnormalities, MK-positive
karyotypes (MKþ ) split into different prognostic subgroups (MKþ and 2 abnormalities: OS 13.4 months, MKþ and 3
abnormalities: 8.0 months, MKþ and 4 abnormalities: 7.9 months and MKþ and X5 abnormalities: 4.9 months; Po0.01). In
multivariate analyses, MK was not an independent prognostic factor. Our data support the hypothesis that a high number of
complex abnormalities, associated with an instable clone, deﬁne the subgroup with the worst prognosis in MDS, independent
of MK.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal disorders of the
hematopoietic stem cell, associated with peripheral cytopenias
and the risk of transformation into acute myeloid leukemia
(AML).1,2 The commonly used prognostic classiﬁcation systems3-6
include the percentage of bone marrow blasts, the extent of
peripheral cytopenias, the transfusion burden and the karyotype
as major prognostic variables in MDS. However, the recently
published revision of the International Prognostic Scoring System
(IPSS-R)4 revealed that the karyotype is the most inﬂuential
prognostic parameter regarding overall survival (OS) as well as
AML-free survival (AMLFS).
A complex karyotype (CK), deﬁned as three or more abnormalities
in one cell,7 is clearly associated with an adverse prognosis.3–5,8,9
However, little is known about prognostically relevant subgroups
within this heterogeneous category. The revised IPSS (IPSS-R)
separates two independent subsets of patients with complex
abnormalities based on the number of abnormalities per clone.
Those with exactly three abnormalities are classiﬁed as poor
whereas patients with more than three abnormalities are assigned
to the group with the worst prognosis.4 Moreover, data from the
German MDS study group demonstrated that the prognostically
worse impact of complex abnormalities increases with the number
of abnormalities per clone.8
In AML, an alternative approach was proposed by Breems
et al.10: monosomal karyotype (MK), deﬁned as at least
two autosomal monosomies or one autosomal monosomy and
one structural abnormality in one cell, was described as a
better indicator for a worse prognosis than CK. Subsequently,
associations of MK with treatment outcome,11–18 occurrence
of TP53-mutations,19,20 speciﬁc copy number alterations20 and
multidrug resistance activity13 were described. However, a recent
publication by Haferlach et al.21 revealed that the use of MK bears
the risk of missing a signiﬁcant subset of patients with an adverse
prognosis in AML.
In MDS, MK was also described as an unfavorable risk
factor.17,22,23 In contrast, Itzykson et al.24 found no signiﬁcant
differences between MK and non-MK in a group of patients with
MDS, treated with 5-azacytidine. Recently, the Spanish Group of
MDS25 demonstrated that MK is not an independent risk factor
for OS and the complexity of the karyotype is the most
important factor predicting prognosis in this disease. Furthermore,
1Department of Hematology and Oncology, University of Go¨ttingen, Go¨ttingen, Germany; 2L Boltzmann Institute for Leukemia Research, Vienna, Austria; 3Institut de Recerca
contra la Leuce`mia Josep Carreras, Badalona, Spain; 4Department of Hematology, University Hospital of Asturias, Oviedo, Spain; 5Department of Hematology, University Hospital
La Fe, Valencia, Spain; 6Department of Hematology, Hospital Germans Trias i Pujol, Barcelona, Spain; 7Department of Human Genetics, University of Duesseldorf, Duesseldorf,
Germany; 8Sonora Quest Laboratories/Laboratory Sciences of Arizona, Cytogenetics Laboratory, Tempe, AZ, USA; 9First Department of Internal Medicine, Tokyo Medical
University, Tokyo, Japan; 10Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; 11Department of Medical Genetics, Medical
University of Vienna, Vienna, Austria; 12Hanusch Hospital, L Boltzmann Institute for Leukemia Research, Vienna, Austria; 13Division of Hematology, Department of Medicine I,
Medical University of Vienna, Vienna, Austria; 14Department of Hematology and Oncology, Marien Hospital, Du¨sseldorf, Germany; 15Department of Hematology and Oncology,
Johannes Hospital, Duisburg, Germany; 16Department of Hematology and Oncology, University of Freiburg, Freiburg, Germany; 17Department of Hematology and Oncology,
Medical University of Innsbruck, Innsbruck, Austria; 18Department of Internal Medicine I, Elisabethinen Hospital, Linz, Austria; 19Section of Hematology/Oncology, University of
Chicago, Chicago, IL, USA; 20University of Rochester, Medical Center, Rochester, NY, USA; 21Division of Hematology, Stanford University Cancer Center, Stanford, CA, USA and
22Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Du¨sseldorf, Germany. Correspondence: Dr J Schanz, Department of Hematology and
Oncology, Georg-August-University, Robert-Koch-Str. 40, 37075 Go¨ttingen, Germany.
E-mail: j.schanz@med.uni-goettingen.de
Received 5 April 2013; revised 30 May 2013; accepted 4 June 2013; accepted article preview online 21 June 2013; advance online publication, 16 July 2013
Leukemia (2013) 27, 1988–1995
& 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13
www.nature.com/leu
investigations based on a patient cohort unbiased by therapy are
not available as yet.
Hence, the main goal of this study was to analyze the
relationship between the number and type of abnormalities,
the occurrence of MK and their inﬂuence on OS and AMLFS in a
cohort of primary, untreated MDS patients.
PATIENTS AND METHODS
Patient cohort
In total, 431 patients with X2 abnormalities were extracted from an
international MDS database and retrospectively analyzed. Owing to the fact
that the deﬁnition of a MK needs at least two abnormalities, patients with
single abnormalities were not considered for analysis. The database contains
2902 patients with primary, untreated MDS. Results from this database as
well as details regarding the patient cohort were published elsewhere,26 but
did not focus on the question of MK. Inclusion criteria in the database were
as follows: unambiguous morphologic diagnosis of MDS or oligoblastic AML
following MDS (blast count p30%), age X16 years, supportive care and
International System for Human Cytogenetic Nomenclature formula
available. The 431 patients with X2 abnormalities were derived from the
following databases: German-Austrian MDS study group (n¼ 185; 43%),
International MDS Risk Analysis Workshop (n¼ 121; 28%), Spanish
Hematological Cytogenetics working group (n¼ 104; 24%) and
International Working Group on MDS Cytogenetics (n¼ 21; 5%). Further
details regarding the study cohort are presented in Table 1. The study was
conducted in accordance with the modiﬁed Declaration of Helsinki.
Bone marrow morphology and peripheral blood count
Bone marrow morphology and peripheral blood count examinations were
performed locally at the participating centers and reviewed as described
elsewhere.26 The classiﬁcation of MDS was done according to the
French–American–British (FAB) classiﬁcation27 and, if available, the World
Health Organization (WHO) classiﬁcation.28
Cytogenetic examinations
Cytogenetic analyses were performed, centrally reviewed and documented
as described elsewhere.26 Patients with missing, incomplete or invalid
International System for Human Cytogenetic Nomenclature formula were
excluded from the analysis. Results from ﬂuorescent in situ hybridization were
not included. The mean number of metaphase cells analyzed was 20 (range
2–194). The number of abnormalities per clone was calculated according to
international guidelines.29 MK was classiﬁed as deﬁned by Breems et al.10:
either two autosomal monosomies or one autosomal monosomy plus one
structural abnormality in one clone. To analyze the impact of monosomies,
trisomies and distinct structural abnormalities, a missing chromosome was
classiﬁed as monosomy, an additional chromosome as trisomy, deletions as
structural losses, additions, insertions and duplications as chromosomal gains,
and balanced translocations, inversions or derivations as structural neutral. In
unbalanced translocations or isochromosomes, the abnormalities were
classiﬁed according to the resulting abnormalities: in der(1;7)(q10;p10), for
example, the abnormality was calculated as a structural loss on chromosome
7 (deletion 7q) and a structural gain on chromosome 1 (trisomy 1q).
Statistical analyses
Statistical analyses were performed using the software SPSS 20.0 (IBM
Corporation, Armonk, NY, USA) and Graph Pad Prism 4 (Graph Pad
Software Inc., La Jolla, CA, USA). Univariate time-to-event analyses were
calculated using the method of Kaplan–Meier.30 OS was calculated from
the time of ﬁrst diagnosis to death or last contact, AMLFS from the time of
diagnosis to AML transformation (as deﬁned by the FAB classiﬁcation) or
last contact without transformation into AML. P-values for differences in
time-to-event analyses were calculated by the log-rank test.31 The
multivariate analysis was done using a Cox proportional hazard model.
In this model, origin of database, gender, age, date of diagnosis,
hemoglobin, absolute neutrophil count, platelet count, bone marrow
blast count, MK, the number of monosomies, trisomies, structural gains,
structural losses, structural neutral abnormalities, the presence of markers
and ring chromosomes were included. Differences in categorical variables
were calculated using a w2 test and differences in continuous variables by
means of the analysis of variance test. Two-sided P-values o0.05 were
considered as signiﬁcant. In view of the explanatory nature of the study, no
adjustment for multiple testing was applied.
RESULTS
Patients
In total, 431 patients with at least two clonal abnormalities
were analyzed; 231 (54%) were men and 200 (46%) were women.
Table 1. Patient cohort
Number of patients Total n (%) No MK n (%) MK n (%) P-value
431 (100.0) 227 (57.7) 204 (47.3)
Database
German-Austrian 185 (42.9) 99 (43.6) 86 (42.2) 0.440
IMRAW 121 (28.1) 57 (25.1) 64 (31.4)
Spanish 104 (24.1) 57 (25.1) 47 (23.0)
IWCG 21 (4.9) 14 (6.2) 7 (4.3)
Gender
Male 231 (53.6) 115 (50.7) 116 (56.9) 0.117
Female 200 (46.4) 112 (49.3) 88 (43.1)
Age (years)
Median 69 69 70 0.264
Range 21–90 21–90 24–89
WHO classificationa
RA/RARS 18 (4.2) 16 (7.0) 2 (1.0) 0.025
RCMD/-RS 50 (11.6) 33 (14.5) 17 (8.3)
RAEB-1 34 (7.9) 19 (8.4) 15 (7.4)
RAEB-2 48 (11.1) 21 (9.3) 27 (13.2)
CMML 1/2 8 (1.9) 6 (2.7) 2 (1.0)
5q- Syndrome 3 (0.7) 3 (1.3) 0 (0.0)
AML 20 (4.6) 10 (4.4) 10 (4.9)
Unclassified 2 (0.5) 1 (0.4) 1 (0.5)
No WHO
classification
248 (57.5) 118 (52.0) 130 (57.5)
FAB classification
RA/RARS 158 (36.7) 110 (48.5) 48 (23.5) o0.0001
RAEB 153 (35.5) 69 (30.4) 84 (41.2)
RAEB-T 68 (15.8) 15 (6.6) 53 (26.0)
CMML 33 (7.7) 21 (9.3) 12 (5.9)
AML 1 (0.2) 1 (0.4) 0 (0.0)
Unclassified 1 (0.2) 1 (0.4) 0 (0.0)
No FAB
classification
17 (3.9) 10 (4.4) 7 (3.4)
Bone marrow blasts (%)
Median 7 4 11 o0.0001
Range 0–30 0–30 0–30
Cytopenias
Hb (g/dl) median 9.0 9.5 8.5 0.007
Hb range 1.0–16.0 2.0–16.0 1.0–14.0
ANC (103/ml)
median
2.0 2.0 2.0 0.097
ANC range 0.0–35.0 0.0–35.0 0.0–27.0
PLT (103/ml)
median
93 109 75 0.001
PLT range 4–999 4–978 10–999
IPSS
Low 11 (4.0) 11 (8.0) 0 (0.0) o0.0001
Intermediate-1 71 (25.9) 57 (41.6) 14 (10.2)
Intermediate-2 89 (32.5) 43 (31.4) 46 (33.6)
High 103 (37.6) 26 (19.0) 77 (56.2)
IPSS-R
Very good 1 (0.4) 1 (0.7) 0 (0.0) o0.0001
Good 30 (11.1) 29 (21.3) 1 (0.7)
Intermediate 39 (14.4) 34 (25.0) 5 (3.7)
Poor 53 (19.6) 33 (24.3) 20 (14.8)
Very poor 148 (54.6) 39 (28.7) 109 (80.7)
Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil
count; CMML, chronic myelomonocytic leukemia; Hb, hemoglobin; IMRAW,
International MDS risk analysis workshop; IPSS, International Prognostic
Scoring System; IPSS-R, Revised International Prognostic Scoring System;
IWCG, International work group on MDS cytogenetics of the MDS
Foundation; FAB, French–American–British; MK, monosomal karyotype;
PLT, platelet count; RA, refractory anemia; RARS, refractory anemia with
ring sideroblasts; RAEB, refractory anemia with excess of blasts; RAEB-T,
refractory anemia with excess of blasts in transformation; WHO, World
Health Organization. aOnly indicated in patients with missing FAB
classification.
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The median age was 69 years (range 21–90 years). The median
year of MDS diagnosis was 1992. Thus, most patients (n¼ 414;
96%) were classiﬁed according to the FAB classiﬁcation. Of these,
168 (39%) were additionally classiﬁed deﬁned by the WHO system.
In 15 (4%) patients, the classiﬁcation was done by the WHO
classiﬁcation exclusively. According to the IPSS-risk group,
11 (4%) patients were classiﬁed as low risk, 71 (26%) as
intermediate-1 risk, 89 (33%) as intermediate-2 risk and 103
(38%) as high-risk MDS. In 157 patients (36%), the IPSS
classiﬁcation was not available. In addition, the risk classiﬁcation
according to IPSS-R was calculated. Further details regarding the
patient cohort are shown in Table 1.
Incidence of MK and correlation with clinical data
An MK-positive karyotype (MKþ ) was detected in nearly half of
patients (n¼ 204; 47%). Patients with MK showed a signiﬁcantly
higher percentage of bone marrow blasts (median 11%)
as compared with those without MK (MK–; 4%; Po0.001).
Accordingly, the distribution of FAB subtypes and IPSS-risk groups
was also signiﬁcantly different (refractory anemia with excess of
blast/refractory anemia with excess of blast in transformation 67%
in MKþ vs 37% in MK–; Po0.0001; intermediate-2/high-risk MDS
90% in MK vs 50% in MK–; Po0.001). The hemoglobin level
(8.5 g/dl in MKþ vs 9.5 in MK–; P¼ 0.007) and platelet count
(75 103/ml in MKþ vs 109 103/ml in MK–; P¼ 0.001) were also
affected by the presence of MK, while no signiﬁcant differences
were observed in the absolute neutrophil count. Regarding age,
gender or origin of database, signiﬁcant differences were not
detected.
Cytogenetic ﬁndings
The number of abnormalities per clone (A/C) was calculated in
each patient. In total, 175 (41%) patients showed a non-CK with
two abnormalities, 60 (14%) a complex abnormal karyotype
with three abnormalities, 44 (10%) a complex abnormal karyotype
with four abnormalities and 152 (35%) a highly CK with ﬁve or
more abnormalities (Table 2). The incidence of MK increased with
the number of abnormalities. In patients with two abnormalities,
13% were MKþ , in complex abnormal patients with 3 abnorm-
alities, 37% were MKþ , in patients with 4 abnormalities, 73%
were MKþ and in highly complex abnormal karyotypes with
X5 abnormalities, 84% showed MK (Po0.01). The median
number of abnormalities was signiﬁcantly higher in MKþ patients
as compared with those with an MK– karyotype (5 vs 2
abnormalities; Po0.01).
MK, deﬁned as one monosomy plus one structural abnormality,
was found in only 20 patients (5%) and a combination of two
monosomies with no additional abnormalities in 2 patients (0.5%).
Furthermore, monosomy 5 and/or monosomy 7, both well-known
poor prognostic markers, were observed in 58% of patients with
MK and only 5% of patients without MK (Po0.01; Table 2). Marker
chromosomes or double minutes, both indicative for an unstable
clone and also associated with a high number of abnormalities
and a poor prognosis, occurred in 44% of MKþ and 13% of
MK– patients (Po0.01). Monosomy 7 was the most observed
monosomy in MK (n¼ 87; 43%), followed by -5 (54; 27%), -18
(42; 21%), -17 (33; 16%), -21 (32; 16%), -20 (29; 14%) and -13
(27; 13%). The mean number of abnormalities per clone is 45 in
most of these monosomies (Supplementary Figure 5a), reﬂecting
the fact that the majority of monosomies occur in highly complex
abnormal karyotypes. An exception was seen in -7, which is also
observed in patients with non-CK. This is also the fact in -X and,
especially, -Y, but these abnormalities are excluded in the
deﬁnition of MK. Interestingly, trisomies are more often associated
with higher number of abnormalities per clone as compared with
monosomies (Supplementary Figure 5b). This highlights the fact
that highly complex abnormal karyotypes, which are MKþ in
the majority of cases, also include a high number of distinct
trisomies. In structural abnormalities, the mean number of
abnormalities per clone is lower as compared with monosomies
or trisomies (Supplementary Figure 5c). Furthermore, the number
of monosomies increases over-proportional with the number of
abnormalities per case (Supplementary Figure 5d). In patients
with highly complex abnormal karyotypes (X5 abnormalities), the
mean number is 2.9 for monosomies, 1.1 for trisomies, 0.8 for
structural gains, 1.3 for structural losses and 1.3 for structural
neutral abnormalities, respectively. This result indicates 2 or more
Table 2. Cytogenetic abnormalities
Total
(n¼ 431)
MK, n (%) P-value
n (%) MK– (n¼ 227) MKþ (n¼ 204)
Number of abn.
2 Abn. 175 (40.6) 153 (67.4) 22 (10.8) o0.01
3 Abn. 60 (13.9) 38 (16.7) 22 (10.8)
4 Abn. 44 (10.2) 12 (5.3) 32 (15.7)
X5 Abn. 152 (35.3) 24 (10.6) 128 (62.7)
Involvement of
-5/-7
130 (30.2) 12 (5.3) 118 (57.8) o0.01
Median number of
abn./clone (range)
3.0 (2–20) 2.0 (2–20) 5.0 (2–18) o0.01
Marker/dminutes
present
119 (27.6) 30 (13.2) 89 (43.6) o0.01
Ring chromosomes 10 (2.3) 4 (1.8) 6 (2.9) NS
IPSS cytogenetic subgr.
Good 0 (0.0) 0 (0.0) 0 (0.0) o0.01
Intermediate 144 (33.4) 136 (59.9) 8 (3.9)
Poor 287 (66.6) 91 (40.1) 196 (96.1)
IPSS-R cytogenetic subgr.
Very good 0 (0.0) 0 (0.0) 0 (0.0) o0.01
Good 45 (10.4) 43 (18.9) 2 (1.0)
Intermediate 99 (23.0) 93 (41.0) 6 (2.9)
Poor 91 (21.1) 55 (24.2) 36 (17.6)
Very poor 196 (45.5) 36 (15.9) 160 (78.4)
Mean number and range
Monosomies 1.4 (0–10) 0.2 (0–2) 2.7 (1–10) o0.01
Trisomies 0.7 (0–14) 0.9 (0–14) 0.4 (0–8) o0.01
Structural gains 0.5 (0–5) 0.3 (0–5) 0.6 (0–5) o0.01
Structural losses 1.0 (0–6) 0.9 (0–4) 1.1 (0–6) o0.05
Structural neutral
abn.
0.8 (0–6) 0.7 (0–4) 1.0 (0–6) o0.01
Monosomy
-1 7 (1.6) 0 (0.0) 7 (3.4) o0.01
-2 5 (1.2) 1 (0.4) 4 (2.0) o0.01
-3 20 (4.6) 0 (0.0) 20 (9.8) o0.01
-4 18 (4.2) 0 (0.0) 18 (8.8) o0.01
-5 60 (13.9) 6 (2.6) 54 (26.5) o0.01
-6 17 (3.9) 1 (0.4) 16 (7.8) o0.01
-7 93 (21.6) 6 (2.6) 87 (42.6) o0.01
-8 18 (4.2) 0 (0.0) 18 (8.8) o0.01
-9 17 (3.9) 0 (0.0) 17 (8.3) o0.01
-10 10 (2.3) 0 (0.0) 10 (4.9) o0.01
-11 13 (3.0) 0 (0.0) 13 (6.4) o0.01
-12 17 (3.9) 0 (0.0) 17 (8.3) o0.01
-13 29 (6.7) 2 (0.9) 27 (13.2) o0.01
-14 15 (3.5) 0 (0.0) 15 (7.4) o0.01
-15 20 (4.6) 0 (0.0) 20 (9.8) o0.01
-16 16 (3.7) 0 (0.0) 16 (7.8) o0.01
-17 33 (7.7) 0 (0.0) 33 (16.2) o0.01
-18 43 (10.0) 1 (0.4) 42 (20.6) o0.01
-19 14 (3.2) 0 (0.0) 14 (6.9) o0.01
-20 29 (6.7) 0 (0.0) 29 (14.2) o0.01
-21 33 (7.7) 1 (0.4) 32 (15.7) o0.01
-22 14 (3.2) 1 (0.4) 13 (6.4) o0.01
-X 14 (3.2) 7 (3.1) 7 (3.4) NS
-Y 35 (8.1) 22 (9.7) 13 (6.4) NS
Abbreviations: Abn., abnormalities; IPSS, International Prognostic Scoring
System; IPSS-R, Revised International Prognostic Scoring System;
MK–, monosomal karyotype absent; MKþ , monosomal karyotype present;
Marker/dminutes, marker chromosomes or double minutes; NS, not
significant; subgr., subgroup; NS (40.05).
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monosomies are usually associated with a number of karyotypes
with X5 abnormalities (Supplementary Figure 5d).
Results from univariate survival analyses
In total, we observed a clear difference in OS as well as AMLFS in
MKþ as compared with MK– (Table 3). The median OS was 24.0
months in MK– vs 6.7 months in MKþ (Po0.01), the median time
to AML transformation was 22.5 months in MK– and 5.0 months in
MKþ (Po0.01). However, classifying the patients according to the
number of abnormalities per case revealed that the poor impact of
MKþ regarding prognosis is only observable in patients witho5
abnormalities (Figure 1a). In highly complex abnormal karyotype
with 5 or more abnormalities, the presence of MK was not
associated with a poorer prognosis as compared with the absence
of MK (Figure 1b). Similar results were observed regarding AMLFS
(Figures 1 c and d). Furthermore; the prognosis of MKþ patients is
clearly inﬂuenced by the number of abnormalities. MKþ patients
with 2 abnormalities show a better prognosis as those with 3, 4 or
X5 abnormalities. The median OS was 13.4, 8.0, 7.9 and 4.9
months, respectively (Po0.001). Finally, MK– patients with X5
abnormalities show a worse prognosis (OS 5.6 months) as MKþ
with two abnormalities (13.4 months) or three or four abnorm-
alities (8.0 and 7.9 months). This highlights the fact that MKþ is
not necessarily associated with the worst prognosis in MDS
patients (Table 3, Figures 2a and b).
Impact of -5/-7 on survival in patients with MK
Monosomy 5 and/or monosomy 7 are the most frequent
monosomies in patients with MK. In total, 69% of patients showed
Table 3. Survival in cytogenetic subgroups
Univariate analysis
OS (months) AMLFS (months)
n Median 95% CI P-value n Median 95% CI P-value
Total
MK– 225 24.4 19.0–29.8 o0.001 198 91.0 26.0–156.0 o0.001
MKþ 197 6.7 5.8–7.6 178 9.0 6.2–11.8
MK– karyotypes
MK– and 2 abn. 153 31.3 24.7–37.9 o0.001 133 91.0 – 0.010
MK– and 3 abn. 38 17.4 13.2–21.6 34 33.0 8.8–57.2
MK– and 4 abn. 12 22.8 7.0–38.6 12 22.0 3.3–40.7
MK– and X5 abn. 22 5.6 0.8–10.4 19 8.3 4.2–12.4
MK– without -5/-7 213 24.4 19.7–29.1 NS 187 91.0 13.0–169.0 NS
MK– with -5/-7 12 17.0 12.6–21.4 11 17.2 8.3–26.1
MKþ karyotypes
MKþ and 2 abn. 22 13.4 10.6–16.2 o0.001 20 12.0 8.0–16.0 NS
MKþ and 3 abn. 21 8.0 5.2–10.8 21 14.7 0.0–44.0
MKþ and 4 abn. 31 7.9 4.6–11.2 27 8.2 2.2–14.2
MKþ and X5 abn. 123 4.9 3.9–5.9 110 7.7 5.7–9.7
MKþ without -5/-7 85 6.6 4.6–8.6 NS 74 7.7 5.3–10.1 NS
MKþ with -5/-7 112 6.8 5.7–7.9 104 9.7 6.5–12.9
Category OS AMLFS
n¼ 269 pts. with complete data n¼ 254 pts. with complete data
n HR 95% CI P-value n HR 95% CI P-value
Monosomal karyotype 134 1.1 0.6-1.9 NS 129 1.1 0.5-2.8 NS
-5 and/or -7 present 88 1.6 1.1–2.5 0.023 86 1.9 1.0–3.5 NS
No monosomy (Ref.) 108 1.0 102 1.0
1 Monosomy 78 1.0 0.6–1.7 NS 76 1.0 0.4–2.2 NS
2 Monosomies 26 1.7 0.7–3.8 NS 25 2.3 0.7–7.9 NS
X3 monosomies 57 1.4 0.7–3.1 NS 54 1.3 0.4–4.3 NS
No trisomy (Ref.) 164 1.0 155 1.0
1 Trisomy 73 1.2 0.9–1.7 NS 70 1.4 0.8–2.3 NS
2 Trisomies 16 1.4 0.8–2.6 NS 16 0.8 0.3–2.5 NS
X3 Trisomies 16 2.9 1.5–5.5 0.001 16 5.0 2.0–12.2 0.000
No structural gain (Ref.) 186 1.0 176 1.0
1 Structural gain 65 1.2 0.8–1.7 NS 63 1.5 0.9–2.5 NS
2 Structural gains 12 1.5 0.7–3.3 NS 11 4.0 1.5–10.8 0.006
X3 Structural gains 6 0.8 0.3–2.0 NS 7 2.0 0.6–6.7 NS
No structural loss (Ref.) 98 1.0 95 1.0
1 Structural loss 114 1.0 0.7–1.4 NS 105 1.1 0.6–2.0 NS
2 Structural losses 44 1.0 0.6–1.7 NS 44 1.1 0.5–2.3 NS
X3 Structural losses 13 1.1 0.5–2.4 NS 13 1.4 0.4–4.8 NS
No structural neutral abn. (Ref.) 169 1.0 158 1.0
1 Structural neutral abn. 37 1.4 0.9–2.2 NS 36 1.0 0.5–2.0 NS
2 Structural neutral abn. 46 1.4 0.9–2.1 NS 45 1.4 0.8–2.7 NS
X3 Structural neutral abn. 17 1.7 0.9–3.1 NS 18 2.2 1.0–4.9 NS
Marker chromosomes/dmin 79 1.8 1.3–2.5 0.001 77 1.5 0.9–2.5 NS
Ring chromosomes 7 2.6 1.0–6.6 0.042 7 4.7 1.5–15.1 0.009
Abbreviations: Abn., abnormalities; AMLFS, AML-free survival; 95% CI, 95% confidence interval; HR, hazard ratio; MDS, myelodysplastic syndrome;
MK–, monosomal karyotype absent; MKþ , monosomal karyotype present; NS, not significant; OS, overall survival; Pts., patients; struct., structural.
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one of these abnormalities. The median survival in patients with
MK in total did not differ between patients with or without
monosomy 5/7 (median OS 6.8 vs 6.6 months, P-value not
signiﬁcant; Table 3). However, by separating MKþ patients
according to the number of abnormalities per case, it became
obvious that the presence of -5/-7 shows a different prognostic
value depending on the complexity of the clone. Owing to the
fact that nearly all patients with double (¼ 2) abnormalities
and MK show -5 or -7 (17/22 patients; 77%) all patients with
o5 abnormalities were coalesced into one group and compared
with patients with X5 abnormalities in the following analyses.
In patients witho5 abnormalities, MK without the involvement of
-5/-7 was associated with a better OS as compared with those with
-5/-7 (12.2 vs 8.2 months, P¼ 0.053), while the presence
of -5/-7 became irrelevant in highly CKs with X5 A/C (4.0 vs 5.0
months, P¼ not signiﬁcant; Figures 3a and b). Regarding AMLFS,
no signiﬁcant differences were found (Figures 3c and d).
Results from multivariate survival analyses
In order to analyze the impact of monosomies, trisomies or
structural abnormalities on survival, a multivariate analysis was
performed. In this analysis, database, age, cytopenias, blast count,
the presence of -5 or -7, 3 or more trisomies, the presence of
marker chromosomes, and ring chromosomes were associated
with a higher risk regarding OS. Concerning AMLFS, database,
bone marrow blast count, three or more trisomies, two structural
gains and the presence of ring chromosomes was identiﬁed as
unfavorable. MK was not identiﬁed as an independent risk factor
for OS or AMLFS (Table 3, Figures 4a and b, Supplementary
Table 4). In addition, three or more trisomies were associated with
a higher risk (hazard ratio 2.9 for OS) as compared with three or
more monosomies (1.4). As mentioned above, three or more
trisomies but not monosomies were an independent risk factor for
AML transformation (Table 3, Figures 4a and b).
DISCUSSION
The presence of a MK deﬁnes an adverse prognostic factor in AML
and MDS.10–18,22,23 However, recent publications addressed
some reasonable doubts concerning the clinical value21,24 and
the independent prognostic impact25 of this karyotype category.
Furthermore, no data on primary, untreated MDS patients,
determining the effect of MK uninﬂuenced by disease altering
therapy or etiology, has been published to date.
Although MK was developed to identify prognostically adverse
subgroups within complex abnormal karyotype abnormalities, its
deﬁnition allows the diagnosis of MK also in patients with two
Figure 1. Impact of MK in patients with o5 or X5 abnormalities per clone regarding OS (a, b) and AMLFS (c, d). HR, hazard ratio (and 95%
confidence interval); MAFS, median AMLFS; mo., months; MOS, median OS.
Figure 2. OS (a) and AMLFS (b) in MKþ patients with 2 abnormalities as compared with MK– patients with highly complex abnormal (X5)
abnormalities. Abn., abnormalities; HR, hazard ratio (and 95% confidence interval); MAFS, median AMLFS; mo., months; MOS, median OS.
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abnormalities, which are, by deﬁnition, not assignable to complex
chromosomal abnormalities. Hence, the prognostic impact of MK
in this group was also investigated in the present study.
In addition, in order to examine the effect of the number of
abnormalities per clone, its interaction with MK was analyzed. The
results clearly show that MK is associated with a high number
of abnormalities, and the presence of distinct unfavorable
cytogenetic abnormalities. Furthermore, the multivariate analyses
revealed that MK is not independent from these parameters.
Remarkably, the distinction between MKþ and MK– does not add
any prognostic information in the group of patients with highly
unstable clones. Remarkably, MK mainly occurs in this group: 63%
of patients with MK have X5 abnormalities while only 13% of
patients with 2 abnormalities show MK. This ﬁnding is also
underlined by the fact that the median number of abnormalities in
MKþ patients is 5.0 as compared with 2.0 abnormalities in non-
MK patients. Furthermore, the MKþ patient group is hetero-
gonous and its prognostic impact is strongly inﬂuenced by the
number of abnormalities. An MK with 2 abnormalities is associated
with a signiﬁcant better prognosis as compared with MKþ and
X5 abnormalities (median OS 13.4 vs 4.9 months; Po0.01) and
associated with a better prognosis as compared with an MK–
karyotype with X5 abnormalities (13.4 vs 5.6 months, Po0.01;
Figure 2). This ﬁnding demonstrates that MK is not necessarily the
group with the worst prognosis, as found elsewere.22 Our data
support the hypothesis that a high number of complex
abnormalities, associated with an unstable clone, deﬁne the
subgroup with the worst prognosis in MDS, independent of MK.
The results from the multivariate analysis underline this by
showing that MK is not an independent prognostic factor in
MDS. Interestingly, the results from the Cox regression revealed
that two monosomies are not prognostically worse as compared
with two trisomies or two structural abnormalities. Actually,
trisomies, mostly accompanied by structural abnormalities, are
often associated with a high number of abnormalities per clone
(Supplementary Figure 5b), a shorter survival and a higher risk of
AML transformation (Figures 4a and b). This is in accordance with
the results from Sole´ et al.,32 showing that a hyperdiploid
karyotype is associated with a very poor prognosis and a 100%
5-year cumulative risk of transformation to AML.
Taken these results together, we conclude that the adverse
prognostic impact of MK in MDS is predominantly based on
contingencies with other, biologically more conclusively
interpretable factors. First, the presence of two monosomies is
associated with a high number of abnormalities in the entire
clone: patients with at least two monosomies show a mean
number of 44 abnormalities in total (Supplementary Figure 5d).
Thus, in the case of MK, there is a high probability that these
monosomies are part of a highly complex abnormal karyotype. In
these patients, the adverse prognosis is well known.3–5,8 Second,
MK detects mainly monosomies 5 and/or 7. This is of prognostic
relevance in patients with a non-highly complex abnormal
karyotype (Figure 3a). In this group of patients, the poor impact
of MK is mainly based on these abnormalities. In the absence of
 5/ 7, MK is associated with a median OS of 12.2 months,
which matches the results from the poor, but not very poor
cytogenetic prognostic subgroup of the IPSS-R.4,26 Owing to the
over-representation of highly complex abnormal karyotypes in
the MK group, this effect remains undetected if the number of
abnormalities per clone is not considered in the analyses. Third, it
is well known that monosomy 5, the second most frequent
monosomy found in MK, is often not a real monosomy, but
is a marker of pronounced clonal instability and is a masked
del(5q), or another structurally rearranged chromosome.33,34 The
Supplementary Figure 6 shows an example: the chromosome
banding analysis detects a MK including monosomy 5, with a total
number of ﬁve abnormalities. However, the accompanying
multicolor ﬂuorescent in situ hybridization uncovered a highly
unstable clone with several unbalanced structural rearrangements.
Finally, in highly complex abnormal karyotypes abnormalities, the
presence or absence of MK is irrelevant. In these patients, clonal
instability predicts the prognosis.
We conclude that the number of abnormalities, rather than MK,
describes the biological background more precisely. However,
the prognostic heterogeneity of complex abnormalities remains
a challenge that needs further investigations in subsequent
Figure 3. Impact of monosomy 5 and/or 7 in MKþ patients with o5 or X5 abnormalities per clone regarding OS (a, b) and AMLFS
(c, d). Abn., abnormalities; HR, hazard ratio (and 95% confidence interval); MAFS, median AMLFS; MOS, median overall survival; no -5/-7, no
monosomy 5 and/or 7 present; -5/-7, monosomy 5 and/or 7 present.
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studies. It is likely that more sophisticated analytical methods will
lead to more precise genomic proﬁling, which has the potential to
provide a more reﬁned classiﬁcation system.
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